



IMPORTANCIA DE LA COLONITZACIÓ BRONQUIAL

Oriol Sibila
Servei de Pneumologia
Hospital de la Santa Creu i Sant Pau
osibila@santpau.cat



UAB
Universitat Autònoma
de Barcelona

Agenda

- 1) colonització bronquial en la MPOC
- 2) mecanismes de defensa pulmonars
- 3) conclusions

Agenda

1) colonització bronquial en la MPOC

2) mecanismes de defensa pulmonars

3) conclusions




- 63 años
- EPOC GOLD D
- FEV1 30% (previo 32%)
- PaO2 54 mmHg (previa 53)
- OCD
- ICS +LABA + LAMA
- Clínicamente estable los últimos 6 meses
- Expectorador habitual

¿Cultivo esputo?




60-70%




30-40%







Variability and effects of bronchial colonisation in patients with moderate COPD

A. Marin^{*,#}, E. Monsó^{*,#}, M. Garcia-Nuñez^{*,#}, J. Sauleda^{#,†,+}, A. Noguera[§], J. Pons[‡],
A. Agusti^{#,†,***} and J. Morera^{*,#}




Airway Inflammation and Bronchial Bacterial Colonization in Chronic Obstructive Pulmonary Disease

Sanjay Sethi, Jane Maloney, Lori Grove, Catherine Wrona, and Charles S. Berenson




Inflamación vía aérea



Airway Bacterial Load and FEV₁ Decline in Patients with Chronic Obstructive Pulmonary Disease


Tom M. A. Wilkinson, Irem S. Patel, Mark Wilks, Gavin C. Donaldson, and Jadwiga A. Wedzicha

Academic Unit of Respiratory Medicine, St. Bartholomew's and Royal London School of Medicine, St. Bartholomew's Hospital, London, United Kingdom





Bacterial Colonization Increases Daily Symptoms in Patients with Chronic Obstructive Pulmonary Disease

Himanshu Desai¹, Karen Eschberger², Catherine Wrona³, Lori Grove³, Aarti Agrawal⁴, Brydon Grant^{3,5}, Jingjing Yin³, G. Iyer Parameswaran^{2,3}, Timothy Murphy³, and Sanjay Sethi^{2,3}




Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations

I S Patel, T A R Seemungal, M Wilks, S J Lloyd-Owen, G C Donaldson, J A Wedzicha





?



Agenda

- 1) colonització bronquial en la MPOC
- 2) mecanismes de defensa pulmonars
- 3) conclusions

Agenda


1) colonització bronquial en la MPOC

2) mecanismes de defensa pulmonars

3) conclusions



FC BARCELONA - REAL MADRID
Previsione: 1-0 Real in 2000 CAMP NOU



Estructurales

Mecanismos de defensa pulmonares



Células de defensa

Productos de secreción

MUCINS (MUC)

SECRETED MUCINS

MUC 2
MUC 5AC
MUC 5B



Science



nature

Natural Antibiotic Function of a Human Gastric Mucin Against *Helicobacter pylori* Infection

Masatomo Kawakubo *et al.*

Science **305**, 1003 (2004);

DOI: 10.1126/science.1099250



LETTER

doi:10.1038/nature12907

Muc5b is required for airway defence

Michelle G. Roy^{1*}, Alessandra Livraghi-Butrico^{2*}, Ashley A. Fletcher^{3**}, Melissa M. McElwee¹, Scott E. Evans¹, Ryan M. Boerner⁴, Samantha N. Alexander¹, Lindsey K. Bellinghausen¹, Alfred S. Song¹, Youlia M. Petrova¹, Michael J. Tuvim¹, Roberto Adachi¹, Irlanda Romo^{1,5}, Andrea S. Bordt⁶, M. Gabriela Bowden^{6,7}, Joseph H. Sisson⁸, Prescott G. Woodruff⁹, David J. Thornton¹⁰, Karine Rousseau¹⁰, Maria M. De la Garza¹, Seyed J. Moghaddam¹, Harry Karmouty-Quintana⁴, Michael R. Blackburn⁴, Scott M. Drouin⁴, C. William Davis², Kristy A. Terrell², Barbara R. Grubb², Wanda K. O'Neal², Sonia C. Flores², Adela Cota-Gomez², Catherine A. Lozupone², Jody M. Donnelly³, Alan M. Watson³, Corinne E. Hennessy³, Rebecca C. Keith³, Ivana V. Yang³, Lea Barthelemy^{1,11}, Peter M. Henson^{1,11}, William J. Janssen^{1,11}, David A. Schwartz³, Richard C. Boucher², Burton F. Dickey¹ & Christopher M. Evans^{1,3}

MUC1b



Science 2004; 305: 1003-1012


Nature 2014; 505: 423-6



MUC5AC and MUC5B Mucins Are Decreased in Cystic Fibrosis Airway Secretions



Markus O. Henke, Armin Renner, Rudolf M. Huber, Michael C. Seeds, and Bruce K. Rubin

Department of Pulmonary Medicine, Philipps-University Marburg, Marburg; Department of Pulmonary Medicine, Klinikum Innenstadt, Ludwig-Maximilians-University, Munich, Germany; and Departments of Pediatrics and of Internal Medicine/Molecular Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina



MUC5AC and MUC5B Mucins Increase in Cystic Fibrosis Airway Secretions during Pulmonary Exacerbation


Markus O. Henke¹, Gerrit John¹, Michele Germann¹, Hermann Lindemann², and Bruce K. Rubin³



MUC5B Is the Major Mucin in the Gel Phase of Sputum in Chronic Obstructive Pulmonary Disease

Sara Kirkham^{1,2}, Umme Kolsum², Karine Rousseau¹, Dave Singh², Jørgen Vestbo^{2,3}, and David J. Thornton¹

¹Wellcome Trust Centre for Cell-Matrix Research, Faculty of Life Sciences, University of Manchester, Manchester, United Kingdom; ²North West Lung Centre, University of South Manchester Hospital National Health Service Foundation Trust, Wythenshawe Hospital, Manchester, United Kingdom; ³Department of Cardiology and Respiratory Medicine, Hvidovre Hospital, Hvidovre, Denmark








ORIGINAL ARTICLE


Secreted mucins and airway bacterial colonization in non-CF bronchiectasis

ORIOL SIBILA,^{1,2} GUILLERMO SUAREZ-CUARTIN,^{1,2} ANA RODRIGO-TROYANO,^{1,2} THOMAS C. FARDON,³ SIMON FINCH,³ EDER FREDDY MATEUS,^{2,4} LAIA GARCIA-BELLMUNT,^{1,2} DIEGO CASTILLO,^{1,2} SILVIA VIDAL,^{2,4} FERRAN SANCHEZ-REUS,^{2,5} MARCOS I. RESTREPO,^{6,7} JAMES D. CHALMERS³






MUC ????




Airway Mucin 2 Is Decreased in Patients with Severe Chronic Obstructive Pulmonary Disease with Bacterial Colonization

Oriol Sibila^{1,2}, Laia Garcia-Bellmunt^{1,2}, Jordi Giner^{1,2}, Ana Rodrigo-Troyano^{1,2}, Guillermo Suarez-Cuartin^{1,2}, Alfons Torrego^{1,2}, Diego Castillo^{1,2}, Ingrid Solanes^{1,2}, Eder F. Mateus^{2,3}, Silvia Vidal^{2,3}, Ferran Sanchez-Reus^{2,4}, Ernest Sala^{5,6}, Borja G. Cosio^{5,6}, Marcos I. Restrepo⁷, Antonio Anzueto⁷, James D. Chalmers⁸, and Vicente Plaza^{1,2}



Stable severe COPD
(n=45)




PPB -
n=29 (69%)

PPB +
n=14 (31%)

MUC BAL
MUC sputum


Airway Mucin 2 Is Decreased in Patients with Severe Chronic Obstructive Pulmonary Disease with Bacterial Colonization

Oriol Sibila^{1,2}, Laia Garcia-Bellmunt^{1,2}, Jordi Giner^{1,2}, Ana Rodrigo-Troyano^{1,2}, Guillermo Suarez-Cuartin^{1,2}, Alfons Torrego^{1,2}, Diego Castillo^{1,2}, Ingrid Solanes^{1,2}, Eder F. Mateus^{2,3}, Silvia Vidal^{2,3}, Ferran Sanchez-Reus^{2,4}, Ernest Sala^{5,6}, Borja G. Cosio^{5,6}, Marcos I. Restrepo⁷, Antonio Anzueto⁷, James D. Chalmers⁸, and Vicente Plaza^{1,2}



Airway Mucin 2 Is Decreased in Patients with Severe Chronic Obstructive Pulmonary Disease with Bacterial Colonization



Oriol Sibila^{1,2}, Laia Garcia-Bellmunt^{1,2}, Jordi Giner^{1,2}, Ana Rodrigo-Troyano^{1,2}, Guillermo Suarez-Cuartin^{1,2}, Alfons Torrego^{1,2}, Diego Castillo^{1,2}, Ingrid Solanes^{1,2}, Eder F. Mateus^{2,3}, Silvia Vidal^{2,3}, Ferran Sanchez-Reus^{2,4}, Ernest Sala^{5,6}, Borja G. Cosio^{5,6}, Marcos I. Restrepo⁷, Antonio Anzueto⁷, James D. Chalmers⁸, and Vicente Plaza^{1,2}





NF- κ B Mediates IL-1 β - and IL-17A-Induced *MUC5B* Expression in Airway Epithelial Cells

Tomoyuki Fujisawa^{1*}, Mary Mann-Jong Chang¹, Sharlene Velichko¹, Philip Thai¹, Li-Yin Hung¹, Fei Huang¹, Newton Phuong¹, Yin Chen², and Reen Wu¹


¹Center of Comparative Respiratory Biology and Medicine, University of California at Davis, Davis, California; and ²Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, Arizona



Inflamación { -elevada
-mantenida } → ↓ secreción MUC














HOSPITAL DE LA
SANTA CREU I
SANT PAU

UNIVERSITAT AUTÒNOMA DE BARCELONA




**Karolinska
Institutet**

Colonized





Non-colonized





Non-Colonized

Colonized



Colonized






Pseudomonas aeruginosa resistance patterns and clinical outcomes in hospitalized exacerbations of COPD

Previous PA isolation

n= 54 AECOPD + *P. aeruginosa*

n= 23 (43%)



PA-S n= 18 (33%)

n= 5 (28%)

PA-R n= 36 (66%)

n= 18 (50%)



***Pseudomonas aeruginosa* resistance patterns and clinical outcomes in hospitalized exacerbations of COPD**

	PA S (n=18)	PA R (n=36)
30-day mortality	4 (22%)	1 (2.8%)
90-day mortality	6 (33%)	3 (8.3%)
Hospital LOS	19.3 (SD28.6)	12.9 (SD7.4)
Intensive care Unit admission	3 (16%)	2 (5.6%)
NIV	5 (27%)	7 (19%)
MV	3 (16%)	1 (2.7%)
Persistence at 90-days	4/8 (50%)	25/30 (83%)

	Not-MDR (n=17)	MDR (n=19)
30-day mortality	1 (5.9%)	0%
90-day mortality	3 (17.6%)	0%
Hospital LOS	13.1 (SD 6.8)	12.8 (SD 8)
Intensive care Unit admission	1 (5.9%)	1 (5.3%)
NIV	5 (31.3%)	2 (10.5%)
MV	0%	1 (5.3%)
Persistence at 90-days	11/14 (75%)	14/16 (87%)

Agenda

- 1) colonització bronquial en la MPOC
- 2) mecanismes de defensa pulmonars
- 3) conclusions

Agenda

1) colonització bronquial en la MPOC

2) mecanismes de defensa pulmonars

3) conclusions

IMPORTANCIA DE LA COLONIZACIÓN BRONQUIAL



IMPORTANCIA DE LA COLONIZACIÓN BRONQUIAL



¿TTO ANTIINFLAMATORIO?



ANTIBIÓTICOS



¿MEDICINA REGENERATIVA?





osibila@santpau.cat